Sinil Pharmaceutical Valuation

012790 Stock  KRW 6,690  10.00  0.15%   
At this time, the company appears to be overvalued. Sinil Pharmaceutical has a current Real Value of W6422.4 per share. The regular price of the company is W6690.0. Our model measures the value of Sinil Pharmaceutical from inspecting the company fundamentals such as Return On Equity of 9.59, operating margin of 0.08 %, and Shares Outstanding of 7.5 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
6,690
Please note that Sinil Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Sinil Pharmaceutical is based on 3 months time horizon. Increasing Sinil Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sinil Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sinil Stock. However, Sinil Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  6690.0 Real  6422.4 Hype  6690.0 Naive  6738.93
The real value of Sinil Stock, also known as its intrinsic value, is the underlying worth of Sinil Pharmaceutical Company, which is reflected in its stock price. It is based on Sinil Pharmaceutical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sinil Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
6,422
Real Value
7,359
Upside
Estimating the potential upside or downside of Sinil Pharmaceutical Co helps investors to forecast how Sinil stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sinil Pharmaceutical more accurately as focusing exclusively on Sinil Pharmaceutical's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
6,4016,5986,796
Details
Hype
Prediction
LowEstimatedHigh
6,6886,6906,692
Details
Naive
Forecast
LowNext ValueHigh
6,7376,7396,741
Details

Sinil Pharmaceutical Total Value Analysis

Sinil Pharmaceutical Co is presently forecasted to have takeover price of 159.61 B with market capitalization of 62.74 B, debt of 139.48 M, and cash on hands of 7.31 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sinil Pharmaceutical fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
159.61 B
62.74 B
139.48 M
7.31 B

Sinil Pharmaceutical Investor Information

About 40.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Sinil Pharmaceutical had 26:25 split on the 28th of December 2022. Sinil Pharmaceutical Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in March.

Sinil Pharmaceutical Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sinil Pharmaceutical has an asset utilization ratio of 47.88 percent. This suggests that the Company is making W0.48 for each dollar of assets. An increasing asset utilization means that Sinil Pharmaceutical Co is more efficient with each dollar of assets it utilizes for everyday operations.

Sinil Pharmaceutical Ownership Allocation

The market capitalization of Sinil Pharmaceutical is W62.74 Billion. Sinil Pharmaceutical maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the company is less than the current market value, you may not be able generate positive returns on investment in the long run.

Sinil Pharmaceutical Profitability Analysis

The company reported the revenue of 61.75 B. Net Income was 6.68 B with profit before overhead, payroll, taxes, and interest of 24.2 B.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sinil Pharmaceutical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sinil Pharmaceutical and how it compares across the competition.

About Sinil Pharmaceutical Valuation

The stock valuation mechanism determines Sinil Pharmaceutical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Sinil Pharmaceutical. We calculate exposure to Sinil Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sinil Pharmaceutical's related companies.
Sinil Pharmaceutical Co., Ltd. manufactures, markets, and sells pharmaceutical products in South Korea. Sinil Pharmaceutical Co., Ltd. was founded in 1971 and is headquartered in Seoul, South Korea. Shinil Pharm is traded on Korean Securities Dealers Automated Quotations in South Korea.

8 Steps to conduct Sinil Pharmaceutical's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sinil Pharmaceutical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sinil Pharmaceutical's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Sinil Pharmaceutical's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Sinil Pharmaceutical's revenue streams: Identify Sinil Pharmaceutical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Sinil Pharmaceutical's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Sinil Pharmaceutical's growth potential: Evaluate Sinil Pharmaceutical's management, business model, and growth potential.
  • Determine Sinil Pharmaceutical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sinil Pharmaceutical's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Complementary Tools for Sinil Stock analysis

When running Sinil Pharmaceutical's price analysis, check to measure Sinil Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinil Pharmaceutical is operating at the current time. Most of Sinil Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinil Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinil Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinil Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance